Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis
ConclusionsIn this study, we found that circulating complement-activating anti-HLA DSAs had a significant deleterious impact on solid organ transplant survival and risk of rejection. The detection of complement-activating anti-HLA DSAs may add value at an individual patient level for noninvasive biomarker-guided risk stratification. Trial registrationNational Clinical Trial protocol ID: NCT03438058.
Source: PLoS Medicine - Category: Internal Medicine Authors: Antoine Bouquegneau Source Type: research
More News: Bone Graft | Cardiology | Clinical Trials | Databases & Libraries | Heart | Heart Transplant | Hepatocellular Carcinoma | Internal Medicine | Kidney Transplant | Kidney Transplantation | Liver | Liver Cancer | Liver Transplant | Lung Transplant | Study | Transplant Surgery | Transplants | Urology & Nephrology